Glenmark Therapeutics Expands Specialty Portfolio With OTIPRIO Co-Promotion Agreement in the U.S. With Otonomy for Acute Otitis Externa Indication

/ -- Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., today announced a co-promotion agreement with Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. Glenmark Therapeutics is dedicated to developing and commercializing a franchise of branded products for Glenmark Pharmaceuticals and is focused in the areas of respiratory and dermatology. Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), formerly GSP 301 Nasal Spray, is the company's leading respiratory pipeline asset and currently under review with the U.S. Food and Drug Administration (FDA) as a treatment of seasonal allergic rhinitis in patients 12 years and older. 'Ryaltris' has been conditionally accepted by the FDA as the brand name.

(Logo: https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg )
"We are pleased to collaborate with Otonomy on this agreement which represents an excellent opportunity to fit within our respiratory franchise and supports our strategy of maintaining commercial emphasis on specialists," said Robert Matsuk, President North America for Glenmark Therapeutics. "With FDA review of our first New Drug Application for Ryaltris well underway, we remain focused on developing new partnerships that bolster our specialty portfolio and commercial footprint in the U.S. This agreement is a clear example of Glenmark Therapeutics' efforts to maximize and grow our presence by pursuing opportunities both through external partnerships and our internal R&D pipeline."
About Glenmark Therapeutics' Respiratory Pipeline
About Glenmark Therapeutics
About Otonomy
About OTIPRIO
Approved Indications for OTIPRIO
OTIPRIO (ciprofloxacin otic suspension) is a fluoroquinolone antibacterial indicated for
- The treatment of pediatric patients 6 months of age and older with bilateral otitis media with effusion undergoing tympanostomy tube placement and
Important Safety Information for OTIPRIO